Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

Abstract Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors rarely elicit complete responses in patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC), as a small population of tumor cells survives due to adaptive resistance. Therefore, we focused on the mechanisms underly...

Full description

Bibliographic Details
Main Authors:	Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Shinsaku Tokuda, Kenji Morimoto, Soichi Hirai, Yohei Matsui, Ryota Nakamura, Masaki Ishida, Hayato Kawachi, Kazue Yoneda, Kazutaka Hosoya, Takahiro Tsuji, Hiroaki Ozasa, Akihiro Yoshimura, Masahiro Iwasaku, Young Hak Kim, Mano Horinaka, Toshiyuki Sakai, Takahiro Utsumi, Shinsuke Shiotsu, Takayuki Takeda, Ryohei Katayama, Koichi Takayama
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-01-01
Series:	npj Precision Oncology
Online Access:	https://doi.org/10.1038/s41698-023-00350-7

Similar Items

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features
by: Keiko Tanimura, et al.
Published: (2022-01-01)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
by: Hayato Mizuta, et al.
Published: (2021-02-01)

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
by: Yuki Shimizu, et al.
Published: (2022-03-01)

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)
by: Hayato Kawachi, et al.
Published: (2023-06-01)

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study
by: Masaki Ishida, et al.
Published: (2022-01-01)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
by: T. Lee Collier PhD, et al.
Published: (2017-10-01)

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
by: Marliese Alexander, B.Pharm(Hons), MPH, PhD, et al.
Published: (2023-04-01)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
by: Yun KM, et al.
Published: (2022-02-01)

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%
by: Shota Takei, et al.
Published: (2024-02-01)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
by: Sara Verdura, et al.
Published: (2022-09-01)

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib
by: Shubin W. Shahab, et al.
Published: (2023-02-01)

Successful treatment of refractory brain metastases from ALK‐positive lung cancer with lorlatinib
by: Yoshiko Nakagawa, et al.
Published: (2022-05-01)

Lorlatinib for ALK‐fused, infant‐type hemispheric glioma with lung metastasis: a case report
by: Mingyao Lai, et al.
Published: (2023-05-01)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
by: Hidetoshi Hayashi, MD, PhD, et al.
Published: (2023-04-01)

ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
by: Huihui Li, BM, et al.
Published: (2023-02-01)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
by: Yuki Takeyasu, MD, et al.
Published: (2022-05-01)

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
by: Zhifeng Ye, et al.
Published: (2023-03-01)

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
by: Esther R. Berko, et al.
Published: (2023-05-01)

4558 Investigating the functional consequences of anaplastic lymphoma kinase (ALK) mutations arising upon Lorlatinib treatment
by: Gabriela Maria Witek, et al.
Published: (2020-06-01)

Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases
by: Yosuke Murakami, et al.
Published: (2024-02-01)

Case report: A patient with ALK-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the ALK inhibitor lorlatinib
by: Dan Liu, et al.
Published: (2024-03-01)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
by: Martin Rupp, et al.
Published: (2023-07-01)

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study
by: Sergey V. Orlov, et al.
Published: (2021-08-01)

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
by: Robert Pirker, et al.
Published: (2019-09-01)

Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer
by: Ryota Nakamura, et al.
Published: (2023-04-01)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
by: Rohit Thummalapalli, MD, et al.
Published: (2023-08-01)

Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience
by: K. K. Laktionov, et al.
Published: (2021-12-01)

From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
by: Laura Fabbri, et al.
Published: (2023-12-01)

Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib
by: Bole Li, et al.
Published: (2023-11-01)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
by: Yasushi Goto, MD, PhD, et al.
Published: (2023-05-01)

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
by: Xiya Ma, et al.
Published: (2023-07-01)

Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
by: Tomoyo Taketa, et al.
Published: (2021-04-01)

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain
by: Wei Chen, et al.
Published: (2020-06-01)

Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study
by: Shunsuke Teraoka, MD, et al.
Published: (2024-03-01)

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report
by: Annamaria Catino, et al.
Published: (2022-03-01)

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
by: Qing Zhou, MD, PhD, et al.
Published: (2023-05-01)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
by: Zhu VW, et al.
Published: (2020-01-01)

A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations
by: Ambritha Balasundaram, et al.
Published: (2024-01-01)

Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report
by: Shota Takei, et al.
Published: (2023-09-01)

Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
by: Maximilian J. Hochmair, et al.
Published: (2020-11-01)